JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Search

Guardant Health Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

87.94 -1.21

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

82.87

Max

89.03

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-36M

-128M

Pardavimai

16M

281M

Pelnas, tenkantis vienai akcijai

-0.5

Pelno marža

-45.684

Darbuotojai

2,490

EBITDA

-37M

-119M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+46.73% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-05-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.7B

12B

Ankstesnė atidarymo kaina

89.15

Ankstesnė uždarymo kaina

87.94

Naujienos nuotaikos

By Acuity

50%

50%

178 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-24 00:00; UTC

Uždarbis

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

2026-04-24 00:00; UTC

Uždarbis

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

2026-04-23 23:47; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

2026-04-23 23:43; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-23 23:43; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-23 23:43; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

2026-04-23 23:13; UTC

Įsigijimai, susijungimai, perėmimai

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

2026-04-23 22:33; UTC

Uždarbis

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

2026-04-23 22:17; UTC

Uždarbis

PLS Executed Offtake Agreement With Ronbay

2026-04-23 22:17; UTC

Uždarbis

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

2026-04-23 22:16; UTC

Uždarbis

PLS Commences Commissioning of Midstream Demonstration Plant

2026-04-23 22:15; UTC

Uždarbis

PLS Group Reaffirms FY26 Guidance for All Metrics

2026-04-23 22:14; UTC

Uždarbis

PLS Group 3Q Cash Margin From Operations A$461M at March 31

2026-04-23 22:14; UTC

Uždarbis

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

2026-04-23 22:13; UTC

Uždarbis

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

2026-04-23 22:12; UTC

Uždarbis

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

2026-04-23 22:12; UTC

Uždarbis

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

2026-04-23 22:11; UTC

Uždarbis

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

2026-04-23 22:10; UTC

Uždarbis

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

2026-04-23 22:09; UTC

Uždarbis

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

2026-04-23 22:08; UTC

Uždarbis

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

2026-04-23 22:04; UTC

Uždarbis

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

2026-04-23 21:56; UTC

Rinkos pokalbiai
Uždarbis

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

2026-04-23 21:48; UTC

Įsigijimai, susijungimai, perėmimai

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

2026-04-23 21:27; UTC

Uždarbis

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

2026-04-23 21:25; UTC

Uždarbis

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

2026-04-23 21:24; UTC

Uždarbis

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

2026-04-23 21:24; UTC

Uždarbis

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

2026-04-23 21:21; UTC

Uždarbis

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

2026-04-23 21:21; UTC

Uždarbis

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

46.73% į viršų

12 mėnesių prognozė

Vidutinis 131.41 USD  46.73%

Aukščiausias 175 USD

Žemiausias 90 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

18 ratings

17

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

178 / 348 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat